Atrium Therapeutics, Inc. Common Stock (RNA) — Capital Reinvestment Ratio
Atrium Therapeutics, Inc. Common Stock (RNA) has a Capital Reinvestment Ratio of 0.05x as of December 2023, meaning it reinvests 0% of its operating cash flow ($16.50 Million) in capital expenditures ($863.00K). See RNA equity financing ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Atrium Therapeutics, Inc. Common Stock Capital Reinvestment Ratio (2019–2019)
This chart tracks Atrium Therapeutics, Inc. Common Stock's Capital Reinvestment Ratio across 1 annual periods. Check RNA cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Atrium Therapeutics, Inc. Common Stock (2019–2019)
Year-by-year Capital Reinvestment Ratio for Atrium Therapeutics, Inc. Common Stock from 2019 to 2019. For live market cap and broader valuation context, see market cap of Atrium Therapeutics, Inc. Common Stock.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2019 | 0.09x | $2.49 Million | $235.00K | — |